Cubist Systematic Strategies, LLC Kymera Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$10.97 - $26.84 $1.05 Million - $2.57 Million	95,580 New	95,580 $2.43 Million
Q4 2022 Feb 14, 2023	BUY	$19.57 - $30.92 $1.63 Million - $2.58 Million	83,494 Added 512.8%	99,776 $2.49 Million
Q3 2022 Nov 14, 2022	SELL	$20.91 - $34.27 $502,049 - $822,822	-24,010 Reduced 59.59%	16,282 $354,000
Q2 2022 Aug 15, 2022	BUY	$14.13 - $42.55 $371,265 - $1.12 Million	26,275 Added 187.45%	40,292 $793,000
Q1 2022 May 16, 2022	BUY	$35.3 - $64.68 $494,800 - $906,619	14,017 New	14,017 $593,000
Q4 2021 Feb 14, 2022	SELL	$49.91 - $65.56 $1.25 Million - $1.64 Million	-24,962 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$47.8 - $66.66 $520,207 - $725,460	10,883 Added 77.3%	24,962 $1.47 Million
Q2 2021 Aug 16, 2021	SELL	$31.08 - $51.95 $336,845 - $563,034	-10,838 Reduced 43.5%	14,079 $683,000
Q1 2021 May 17, 2021	BUY	$35.64 - $85.46 $888,041 - $2.13 Million	24,917 New	24,917 $968,000

186

65.5M

49.6K

17K

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.01B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.